Alimera Sciences Stock Price and Value Analysis

Should you buy Alimera Sciences stock? (NasdaqGM:ALIM). Let's see how it does in our automated value investing analysis system.

  • This company has fluctuating growth.
  • This company is solid.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ALIM Numbers

ALIM Price
(Alimera Sciences stock price per share)
[?] PE Ratio versus Sector 27% lower than other Healthcare stocks
[?] PE Ratio versus Industry 93% lower than other Unknown stocks
[?] Cash Yield -290.82%
[?] Free Cash Flow Jitter 32%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 21,596 shares shorted. With 5,168,666 shares available for purchase and an average trading volume over the past 10 trading days of 33,530, it would take at least 0.644 days for all of the short holders to cover their shorts.

Is Alimera Sciences Stock on Sale?

Based on our analysis, we believe that you should not buy Alimera Sciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ALIM Stock?

Does Alimera Sciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.